


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hu et al.

Application Serial No.: 09/219,442

Filed: December 23, 1998

For: Vascular Endothelial Growth Factor 2



Group Art Unit: 1646

Examiner: Saoud, C.

Atty. Docket No.: PF112P2D1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-DY listed on the attached Form PTO-1449.

Copies of references AA-DY were submitted by Applicants or cited by the Examiner in connection with U.S. Patent Application Serial No. 08/999,811, filed December 24, 1997, U.S. Patent Application Serial No. 08/824,996, filed March 27, 1997, and U.S. Patent Application Serial No. 08/465,968, filed June 6, 1995, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the files of the above-listed applications for copies of references AA-DY.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding clone of the captioned application are related to: (1) SEQ ID NO:1383 in copending U.S. Patent application No. 08/196,481; (2) SEQ ID NO:10614 in copending U.S. Patent Application No. 08/196,363; (3) SEQ ID NO:1203 in copending U.S. Patent Application No. 08/196,482; and (4) SEQ ID NO:13645 in copending U.S. Patent Application No. 08/276,163.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425.

Respectfully submitted,

Dated: 12/15/99


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

Enclosure
MW/lcc


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HU et al.

Serial No.: 09/219,442

Filed: December 23, 1998

For: Vascular Endothelial Growth Factor-2



Group Art Unit: 1646

Examiner: Saoud, C.

Atty. Docket No.: PF112P2D1

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$6,288.


The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		SMALL ENTITY	OTHER THAN A SMALL ENTITY		
Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra	Rate	Add. Fee	or	Rate	Add. Fee
Total	325	Minus	32	=	293	X11	\$ **	X22	\$ 5,274.00
Indep	17	Minus	4	=	13	X40	\$ **	X82	\$ 1,014.00
First Presentation of Multiple Dep. Claims					+ 135	\$ **		+ 270	\$ **
Total						\$ **	or	Total	<u>\$ 6,288.00</u>

Please charge the required fee, and any other fee deemed necessary, to Deposit Account No. 03-3425. A duplicate of this sheet is enclosed.

Respectfully submitted,

Dated: 12/15/99


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772